Home » Health » a French laboratory aims for commercialization by 2025

a French laboratory aims for commercialization by 2025

With a vaccine, the headaches related to Lyme disease could finally disappear. Because with this disease, the most annoying is the uncertainty. With symptoms of migrating spots quite difficult to identify and long delays before the onset of serious ailments, after years of indifference, the trend is towards strong antibiotic treatment by prevention. An excess that we can understand, because for doctors who see patients without visible signs of disease, the diagnosis is difficult.

The announcement from the Nantes laboratory Valneva is therefore encouraging. The director of the establishment, Franck Grimaud, said that a vaccine could be available to the general public by 2025. ” This bacterial infection is transmitted by ticks, especially in the countryside and in wooded areas, and has grown considerably over the past 20 years. Lyme disease, often asymptomatic, can nonetheless lead to heart and neurological problems if left untreated. Between 2017 and 2018, its incidence rate was 104 cases per 100,000 inhabitants, according to the Ministry of Health. In 2018, 67,000 new cases were identified in France »Reports The Dispatch. While the laboratory director made the announcement to FranceInfo.

« We started research ten years ago for the development of a vaccine that is suitable for European and American strains, explains the CEO of the laboratory to our colleagues. The first tests aimed at testing the safety of the vaccine on humans have already passed. We are in the process of taking a second step which is to test the best volume / efficiency ratio. »Explains Franck Grimaud.

From 2022, the vaccine will be tested on more than fifteen thousand people, including a large group on placebo. In partnership with the American laboratory Pfizer, this last phase could be the last before the marketing of a vaccine.


Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.